Company Filing History:
1 out of 159 
1 out of 8 Years Active: 2025
Title: Innovations of Quanren Wang in Tumor Treatment
Introduction
Quanren Wang is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the treatment of tumors. His innovative approach combines existing therapies to enhance their effectiveness and reduce adverse effects.
Latest Patents
Wang holds a patent for the "Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors." This patent outlines a method that utilizes an anti-PD-1 antibody alongside famitinib to create a drug aimed at treating tumors. The technical solution presented in this patent emphasizes controllable and tolerable toxicity. Additionally, the drug combination effectively mitigates adverse reactions associated with the anti-PD-1 antibody, such as reactive capillary endothelial proliferation.
Career Highlights
Throughout his career, Quanren Wang has worked with prominent companies in the biopharmaceutical sector. Notably, he has been associated with Jiangsu Hengrui Medicine Company Ltd. and Suzhou Suncadia Biopharmaceuticals Co., Ltd. His work in these organizations has contributed to advancements in cancer treatment and drug development.
Collaborations
Wang has collaborated with several professionals in his field, including Lianshan Zhang and Qing Yang. These partnerships have fostered innovation and the sharing of knowledge, further enhancing the impact of his work.
Conclusion
Quanren Wang's contributions to tumor treatment through his innovative patent and collaborations with industry professionals highlight his role as a significant inventor in the biopharmaceutical field. His work continues to pave the way for advancements in cancer therapies.